Aceragen (Aceragen) Accounts Payable & Accrued Expense : $10.61 Mil (As of Mar. 2023)

View and export this data going back to 1996. Start your Free Trial

What is Aceragen Accounts Payable & Accrued Expense?

Aceragen's quarterly accounts payable & accrued expense declined from Sep. 2022 ($17.45 Mil) to Dec. 2022 ($15.11 Mil) and declined from Dec. 2022 ($15.11 Mil) to Mar. 2023 ($10.61 Mil).

Aceragen's annual accounts payable & accrued expense declined from Dec. 2020 ($6.40 Mil) to Dec. 2021 ($4.65 Mil) but then increased from Dec. 2021 ($4.65 Mil) to Dec. 2022 ($15.11 Mil).

Aceragen Accounts Payable & Accrued Expense Historical Data

The historical data trend for Aceragen's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aceragen Accounts Payable & Accrued Expense Chart

Aceragen Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

9.02

7.92

6.40

4.65

15.11

Aceragen Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															3.58	4.52	17.45	15.11	10.61

Aceragen Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Aceragen (Aceragen) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aceragen Inc (NAS:ACGN) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

505 Eagleview Boulevard, Suite 212, Exton, PA, USA, 19341

Website

https://www.aceragen.com

Aceragen Inc is a clinical-stage biopharmaceutical company committed to transforming the care of people living with rare pulmonary and rheumatic diseases. The company portfolio includes late-stage programs based on well-established biological principles that are developing to be inventive therapeutics capable of addressing the unmet medical needs of individuals living with rare diseases.

Executives

Vincent Milano	director, officer: President & CEO	C/O VIROPHARMA INC, 405 EAGLEVIEW BLVD, EXTON PA 19341
Maxine Gowen	director
Pillar Invest Corp	director, 10 percent owner	C/O PILLAR INVEST OFFSHORE SAL, STARCO CENTER, BLOC B FL3, OMAR DAOUK ST, BEIRUT M8 2020-3313
Atul Chopra	10 percent owner	C/O ACERAGEN, INC., 15 TW ALEXANDER DRIVE, DURHAM NC 27709
John Clayton Taylor	director, officer: Chief Executive Officer	C/O ACERAGEN, INC., 15 TW ALEXANDER DRIVE, DURHAM NC 27709
Carl N Kraus	officer: Chief Medical Officer	C/O ACERAGEN, INC., 15 TW ALEXANDER DRIVE, DURHAM NC 27709
Andrew R Jordan	officer: Chief Strategy Officer	C/O GUILFORD PHARMACEUTICALS INC, 6611 TIBUTARY ST., BALTIMORE MD 21224
Daniel Salain	officer: Chief Operating Officer	C/O GRAYBUG VISION, INC., 275 SHORELINE DRIVE, SUITE 450, REDWOOD CITY CA 94065
Ronald J Wooten	director
Nq Pof V Gp, Ltd.	director, other: See Remarks	4208 SIX FORKS ROAD, SUITE 920, RALEIGH NC 27609
Novaquest Co-investment Fund Xv, L.p.	director, other: See Remarks	4208 SIX FORKS ROAD, SUITE 920, RALEIGH NC 27609
John J. Kirby	officer: V.P. of Finance, PFO & PAO	C/O IDERA PHARMACEUTICALS, INC., 505 EAGLEVIEW BLVD., SUITE 212, EXTON PA 19341
Michael R Dougherty	director	C/O ADOLOR CORP, 700 PENNSYLVANIA DR, EXTON PA 19341
Elizabeth Ann Tarka	officer: Chief Medical Officer	111 WAVERLY CIRCLE, PHOENIXVILLE PA 19460
Bryant David Lim	officer: SVP & General Counsel	C/O IDERA PHARMACEUTICALS, INC., 505 EAGLEVIEW BLVD., SUITE 212, EXTON PA 19341